CN201123923Y - Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome - Google Patents
Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome Download PDFInfo
- Publication number
- CN201123923Y CN201123923Y CNU2007200593445U CN200720059344U CN201123923Y CN 201123923 Y CN201123923 Y CN 201123923Y CN U2007200593445 U CNU2007200593445 U CN U2007200593445U CN 200720059344 U CN200720059344 U CN 200720059344U CN 201123923 Y CN201123923 Y CN 201123923Y
- Authority
- CN
- China
- Prior art keywords
- liver
- artificial liver
- bioartificial
- dialysis system
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model discloses a mixed artificial liver system capable of treating multiple organ dysfunction syndrome, which comprises two parts: a non-bioartificial liver and a bioartificial liver. The utility model is characterized in that: the non-bioartificial liver is a protein dialysis system, and a blood purification outlet of the protein dialysis system is connected with a blood inlet of the bioartificial liver. The utility model combines the protein dialysis system and the mixed artificial liver system for the first time, forms a novel mixed artificial liver system, integrates the respective advantages of the protein dialysis system and the mixed artificial liver system at present, also enhances the vitality of the bioartificial liver, ensures that the mixed artificial liver system can be extended to be applied in treating the multiple organ dysfunction syndrome and achieve the more ideal treatment effect, and can produce good treatment effect on other diseases that the outbreak mechanisms relate to the systemic inflammatory response syndrome (eg. hepatic failure).
Description
Technical field
This utility model relates to the artificial liver in the armarium, particularly the mixed biology artificial liver system that is combined by abiotic artificial liver and bioartificial liver.
Background technology
The mixed biology artificial liver system comprises abiotic artificial liver and bioartificial liver two large divisions.Its ultimate principle is to utilize abiotic artificial liver that blood samples of patients is carried out the purified treatment in early stage, and the hepatocyte among the bioartificial liver substitutes hepatocellular synthetic, the conversion of patient, metabolism and secretory function.Existing mixed biology artificial liver system is crossed because of systemic inflammatory response aspect the multiple organ dysfunction syndrome that causes by force in treatment, can't reach ideal therapeutic effect.Main cause has: 1, the abiotic artificial liver in the system only is simply processing is dialysed, filtered to blood, can't remove protein binding toxin in the blood and macromole toxin, the factor; 2, the bioartificial liver in the system can play the effect of compensatory human hepatocyte's functions such as synthetic, conversion, metabolism and secretion, but since abiotic artificial liver to remove toxin in earlier stage not ideal enough, bioartificial liver's therapeutical effect is subjected to limiting significantly; 3, the abiotic artificial liver in the system mainly adopt methods such as hemodialysis, activated carbon adsorption, plasmapheresis to blood dialyse, processing such as absorption, adopt hemodialysis can not remove big-and-middle molecule poisonous substance, adopt the method for activated carbon adsorption septicemia element to make hemocyte impaired easily, cause hemolytic disease, the method of plasmapheresis needs a large amount of external source blood plasma, not only the blood plasma source is difficult, and pathophorous risk is very high; 4, the pathogenesis of multiple organ dysfunction syndrome is relevant with systemic inflammatory response syndrome, the contained toxicant of this class patient's blood is complicated especially, even purification through abiotic artificial liver, still can seriously jeopardize the hepatocellular life among the bioartificial liver, cause bioartificial liver's effective acting time very short, almost do not reach therapeutic effect.Based on above-mentioned multiple reason, also have no talent clinically successfully with of the treatment of mixed biology artificial liver system applies at present in multiple organ dysfunction syndrome.
Recently the another kind of blood cleaning equipment of Chu Xianing is the albumen dialysis system.The albumen dialysis system can effectively be removed the various types of large, medium and small molecule metabolites matter such as protein binding toxin in the blood, and need not to carry out plasmapheresis, but the albumen dialysis system does not possess the effect of mixed biology artificial liver system, functions such as synthetic, conversion that can not compensatory human hepatocyte, metabolism and secretion are not reaching ideal effect aspect the treatment multiple organ dysfunction syndrome yet.
Generally speaking, also do not have at present a kind of at the armarium of obtaining ideal effect aspect the treatment multiple organ dysfunction syndrome.
Summary of the invention
The purpose of this utility model provides a kind of hybrid artificial liver system for the treatment of multiple organ dysfunction syndrome.
For this reason, hybrid artificial liver described in the utility model system comprises abiotic artificial liver and bioartificial liver two large divisions, its main feature is that described abiotic artificial liver is the albumen dialysis system, and the blood purification delivery outlet of albumen dialysis system is connected with bioartificial liver's blood input port.During system works, the blood of exporting in patient's body is introduced into the albumen dialysis system, by the various types of large, medium and small molecule metabolites matter such as protein binding toxin in the albumen dialysis system removing blood samples of patients, the blood that will purify inputs to the bioartificial liver immediately then, utilize the functions such as synthetic, conversion, metabolism and secretion of the compensatory human hepatocyte of hepatocyte among the bioartificial liver, at last in the blood flowing patient body that reaches desirable clean-up effect of bioartificial liver's output.Because this utility model utilizes the albumen dialysis system that blood samples of patients is carried out the purified treatment in early stage in the hybrid artificial liver system, can effectively remove polytype toxin and inflammatory mediators such as protein binding toxin, so in the process of purification of toxic matter complicated multiple organ dysfunction syndrome patient's blood especially, can significantly reduce toxicant in the blood to the hepatocellular damage in the hybrid artificial liver system, the vitality of bioartificial liver in the obvious enhancing system, prolong bioartificial liver's effective acting time, thereby obtaining ideal treatment aspect the treatment multiple organ dysfunction syndrome.
The utility model has the advantages that first the albumen dialysis system is combined with the mixed biology artificial liver system, form a kind of new mixed biology artificial liver system, not only integrated present albumen dialysis system and mixed biology artificial liver system advantage separately, and strengthened bioartificial liver's vitality, the mixed biology artificial liver system not only can be extended to treat multiple organ dysfunction syndrome and obtain better therapeutic effect, and for other pathogenesis and systemic inflammatory response syndrome diseases associated, for example liver failure can produce excellent curative equally.
Description of drawings
Fig. 1 is the structural representation of this utility model embodiment.
The specific embodiment
Referring to Fig. 1, the abiotic artificial liver in the right frame of broken lines 1 expression hybrid artificial liver system, the bioartificial liver in the left side frame of broken lines 2 expression hybrid artificial liver systems, two parts are integrated and constitute novel hybrid artificial liver system.Compare with existing hybrid artificial liver system, abiotic artificial liver 1 of the present utility model is a cover albumen dialysis system.The blood purification delivery outlet of albumen dialysis system is connected with bioartificial liver's blood input port.In albumen dialysis system 1, directly the parts that blood is purified are albumen dialysers 4.The MARS albumen dialyser that albumen dialyser 4 can directly adopt TERAKLIN company to produce.Can reuse in order to make protein liquid, the albumen dialysis system of present embodiment includes the circulation of protein liquid purifying regeneration, high flux filter 8 is adopted in this circulation, protein liquid port of export series connection active carbon adsorber 10 and resin absorption device 11 at high flux filter 8, filter membranes in the high flux filter 8 are that the polymer with propylene and methanesulfonic sodium is the combined polymerization film that material is made, and the average pore size of film is 178nm.Compare with existing albumen dialysis system, because present embodiment has adopted high flux filter 8 in the circulation of protein liquid purifying regeneration, and adopted filter membrane with described feature, therefore can alleviate the burden of active carbon adsorber 10 and resin absorption device 11 greatly, make active carbon adsorber 10 and resin absorption device 11 not be prone to saturated, can keep absorbability for a long time to the protein binding toxin in the protein liquid, make the protein liquid clean-up effect better, more lasting, thereby make the albumen dialysis system can be more effective, purge away the poison in one's blood for the bioartificial liver enduringly, further strengthen bioartificial liver's vitality, make whole hybrid artificial liver system obtain better therapeutic effect aspect the treatment multiple organ dysfunction syndrome.The above is a preferred forms of the present utility model, if do not consider the repeated use of protein liquid, also can only constitute the simplest albumen dialysis system by albumen dialyser 4 and necessary infusion pump.
In bioartificial liver 2, main parts are doughnut cast bioreactor 5 regulating liver-QI cell culture systems 7.Pump 6 orders about hepatocyte suspension and circulates between doughnut cast bioreactor 5 regulating liver-QI cell culture systems 7.The operation principle of brief description present embodiment: in albumen dialysis system 1, the inner chamber of blood samples of patients process albumen dialyser 4 under pump 3 drives, with the reaction of dialysing of the protein liquid (adopting albumin liquid usually) in albumen dialyser 4 exocoels, various types of large, medium and small molecule metabolites matter such as the protein binding toxin in the blood are transferred in the protein liquid.Meanwhile, contaminated protein liquid is under the driving of pump 9, pass through high flux filter 8, activated carbon adsorption device 10 and resin absorption device 11 successively, protein liquid after the purification comes back to the exocoel of albumen dialyser 4, in this process, the discarded liquid that has toxin imports waste collection jar 13 from 8 discharges of high flux filter.In bioartificial liver 2, enter the inner chamber of doughnut cast bioreactor 5 from the blood of albumen dialysis system 1 output, have an effect with the hepatocyte suspension in the exocoel of doughnut cast bioreactor 5, utilize the functions such as synthetic, conversion, metabolism and secretion of the compensatory human hepatocyte of hepatocyte in the suspension, make blood obtain final purification.Blood flows back to human body from 5 outputs of doughnut cast bioreactor at last.
As further improvement, present embodiment also is parallel with displacement liquid feeder 12 at the protein liquid port of export of high flux filter 8.The displacement liquid that displacement liquid feeder 12 is provided enters the exocoel of albumen dialyser 4 with protein liquid.By regulating the solute concentration of displacement liquid, the flow-rate ratio of perhaps regulating displacement liquid and discarded liquid can reach the therapeutical effect of regulating patient's water, electrolyte, acid-base balance.For example the potassium ion in the blood samples of patients is on the low side, can provide high potassium displacement liquid by displacement liquid feeder 12, make displacement liquid enter the exocoel of albumen dialyser 4 with the protein liquid after purifying, potassium ion in the displacement liquid enters blood through the dialyzer of albumen dialyser 4, improves the concentration of potassium ion in the blood samples of patients with this.Can also replenish protein liquid for system by displacement liquid feeder 12.
Claims (3)
1, a kind of hybrid artificial liver system for the treatment of multiple organ dysfunction syndrome, comprise abiotic artificial liver and bioartificial liver two large divisions, it is characterized in that: described abiotic artificial liver is the albumen dialysis system, and the blood purification delivery outlet of albumen dialysis system is connected with bioartificial liver's blood input port.
2, hybrid artificial liver as claimed in claim 1 system, it is characterized in that: described albumen dialysis system comprises the circulation of protein liquid purifying regeneration, this circulation includes the high flux filter, the protein liquid port of export at the high flux filter is in series with active carbon adsorber and resin absorption device, filter membrane in the high flux filter is that the polymer with propylene and methanesulfonic sodium is the combined polymerization film that material is made, and the average pore size of film is 178nm.
3, hybrid artificial liver as claimed in claim 2 system, it is characterized in that: the protein liquid port of export of high flux filter is parallel with the displacement liquid feeder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200593445U CN201123923Y (en) | 2007-11-09 | 2007-11-09 | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200593445U CN201123923Y (en) | 2007-11-09 | 2007-11-09 | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201123923Y true CN201123923Y (en) | 2008-10-01 |
Family
ID=39997339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007200593445U Expired - Fee Related CN201123923Y (en) | 2007-11-09 | 2007-11-09 | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201123923Y (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421467A (en) * | 2009-03-13 | 2012-04-18 | 梅约医学教育与研究基金会 | Bioartificial liver |
| CN103251996A (en) * | 2013-04-02 | 2013-08-21 | 周春华 | Portable multiple organ support integration machine |
| CN104349802A (en) * | 2012-11-08 | 2015-02-11 | 甘布罗伦迪亚股份公司 | Albumin pump control in a MARS treatment apparatus |
| CN104524653A (en) * | 2014-07-05 | 2015-04-22 | 黄昱 | Artificial liver and blood purification system |
| CN106267400A (en) * | 2016-07-29 | 2017-01-04 | 武汉仝干医疗科技股份有限公司 | Four-in-one formula bioartificial liver's on-line monitoring and heated at constant temperature integrated system |
| US9650609B2 (en) | 2002-06-07 | 2017-05-16 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
| CN110152090A (en) * | 2019-06-18 | 2019-08-23 | 长沙医学院 | A kind of transfusion set of self blood supply circulating purification |
-
2007
- 2007-11-09 CN CNU2007200593445U patent/CN201123923Y/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9650609B2 (en) | 2002-06-07 | 2017-05-16 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
| CN102421467A (en) * | 2009-03-13 | 2012-04-18 | 梅约医学教育与研究基金会 | Bioartificial liver |
| EP2405957A4 (en) * | 2009-03-13 | 2017-07-12 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
| US10130748B2 (en) | 2009-03-13 | 2018-11-20 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
| US10792410B2 (en) | 2009-03-13 | 2020-10-06 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
| CN104349802A (en) * | 2012-11-08 | 2015-02-11 | 甘布罗伦迪亚股份公司 | Albumin pump control in a MARS treatment apparatus |
| CN103251996A (en) * | 2013-04-02 | 2013-08-21 | 周春华 | Portable multiple organ support integration machine |
| CN104524653A (en) * | 2014-07-05 | 2015-04-22 | 黄昱 | Artificial liver and blood purification system |
| CN106267400A (en) * | 2016-07-29 | 2017-01-04 | 武汉仝干医疗科技股份有限公司 | Four-in-one formula bioartificial liver's on-line monitoring and heated at constant temperature integrated system |
| CN106267400B (en) * | 2016-07-29 | 2018-06-19 | 武汉仝干医疗科技股份有限公司 | Four-in-one formula bioartificial liver monitors on-line and heated at constant temperature integrated system |
| CN110152090A (en) * | 2019-06-18 | 2019-08-23 | 长沙医学院 | A kind of transfusion set of self blood supply circulating purification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN201123923Y (en) | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome | |
| CN105025951B (en) | For the system and method for multi-functional volume fluid control | |
| US9302038B2 (en) | Method and apparatus for limiting diafiltrate waste | |
| JP3011463B2 (en) | Therapeutic blood purification apparatus and method for producing transfusion for hemodiafiltration (HDF) | |
| CN103263704B (en) | Be equipped with the plasmapheresis absorption filtration cleaning system of slurry storing bag | |
| JP2010507464A (en) | Liquid-saving cascade hemofiltration | |
| CN105916532A (en) | Redox controlled electrosorption and decomposition device for the purification of blood and other fluids | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| CN203507201U (en) | Separating type hemodialysis absorber | |
| CN205073379U (en) | Plasma exchange adsorbs filters clean system | |
| JP5671528B2 (en) | Dialysis machine | |
| CN106344985A (en) | Multifunctional regenerative blood purification system | |
| CN204521750U (en) | A kind of artificial liver and blood purification system | |
| US20080011682A1 (en) | Method And Device For Downgrading At Least One Component Of A Fluid Medium | |
| CN203354984U (en) | Plasma exchange adsorption filtration purification system for preparing square plasma storage pond | |
| RU93276U1 (en) | EXTRACORPORAL BLOOD CLEANING DEVICE | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| CN101455864B (en) | Mixed biology artificial liver vitro supporting device | |
| CN201320317Y (en) | Hybrid biological artificial liver extracorporeal supporting device | |
| JP4201313B2 (en) | Toxic substance binding albumin removal system | |
| CN203280813U (en) | Plasma exchange absorption filtering purifying system provided with plasma storage bag in matched mode | |
| JP4183036B2 (en) | Blood purification apparatus and regeneration method thereof | |
| CN208552666U (en) | A kind of plasma exchange dialysis adsorption system | |
| EP2295092B1 (en) | Haemodiafiltration set | |
| WO2021138461A1 (en) | Devices and methods for reducing rejection of a transplanted organ in a recipient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081001 Termination date: 20121109 |